35Pharma Presents Preclinical Results for HS135, a Novel Activin and GDF Ligand Trap, at ERS 2022

- **HS135** is a rationally designed receptor ectodomain-based Activin and GDF ligand trap demonstrating best-in-class potency for optimal target engagement
- **HS135** was well tolerated in a non-human primate pilot toxicology study investigating doses of up to 30 mg/kg
- **HS135** has commenced IND enabling development

Montreal, QC, Canada (Sept 6, 2022) – 35Pharma, a biopharmaceutical company that designs and develops biologics for cardiopulmonary diseases, today presented preclinical results from its HS135 program at the European Respiratory Society (“ERS”) International Congress 2022 in Barcelona, Spain (Sept. 4 – 6, 2022).

Activins and GDFs are extensively validated targets driving the pathophysiology of cardiopulmonary diseases. While previous activin targeting agents have shown great therapeutic promise in clinical trials, full pathway inhibition remains a challenge.

HS135 is an activin receptor ectodomain-based Fc-fusion protein that has been rationally designed to achieve optimal rebalancing of pathological and homeostatic ligands. The data reported at ERS 2022 today demonstrate that HS135 achieves best-in-class potency against pathological Activin and GDF targets and has the potential to be dosed to full pathway inhibition.

**Highlights of the data presented include:**

- HS135, an engineered activin receptor type IIB (ActRIIB) based ligand trap, achieves best-in-class potency on Activin A, GDF-8 and GDF-11 compared to wild type ActRIIA-Fc or ActRIIB-Fc
- In primary human pulmonary arterial smooth muscle cells and mouse lung tissue, HS135 was more effective than ActRIIA-Fc at reducing target gene expression
- In a non-human primate pilot toxicology study investigating doses of up to 30 mg/kg, HS135 was well tolerated, no adverse changes in hematological parameters or bleeding events were observed

Maureen O’Connor, Chief Scientific Officer and President of 35Pharma commented: “The results presented today demonstrate that HS135 exhibits a best-in-class ligand neutralization profile to achieve optimal rebalancing of Activin and BMP pathways. In addition, HS135 avoids haematological side effects which supports dosing to maximal biological activity.”

**About 35Pharma and HS135**

35Pharma is a biopharmaceutical company that designs and develops best-in-class transforming growth factor-beta (TGF-beta) superfamily ligand traps for cardio-pulmonary and -metabolic diseases. HS135 is a multi-specific receptor ectodomain ligand trap designed to achieve maximum neutralization of Activins & GDFs, clinically validated drivers of cardio-pulmonary and -metabolic disease. HS135 is undergoing preclinical development and is projected to enter human clinical trials in 2023.

**Contact**
Julia Schoeiermann, VP Business Development, 35Pharma
info@35pharma.com

For more information, please visit [www.35pharma.com](http://www.35pharma.com).